Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-R24 monoclonal antibodies - Viragen

Drug Profile

Research programme: anti-R24 monoclonal antibodies - Viragen

Alternative Names: Anti-GD3 monoclonal antibody - Viragen; Anti-R24 monoclonal antibody - Viragen; VG 101

Latest Information Update: 08 May 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Viragen
  • Class Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 08 May 2007 Discontinued - Preclinical for Malignant melanoma in USA (IV-infusion)
  • 10 Nov 2004 Preclinical trials in Malignant melanoma in USA (IV-infusion)
  • 27 Jul 2004 The anti-R24 monoclonal antibody is available for licensing (http://www.viragen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top